Akebia Therapeutics Hits New 52-Week Low at $1.49

Akebia Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.49 on November 21, 2025. This decline highlights the company's ongoing struggles in a competitive market, particularly as it has underperformed significantly compared to the S&P 500, which has seen a return of 11.0% over the past year.
Despite a one-year performance of 42.2%, Akebia's financial metrics indicate challenges, including a negative return on equity of -92.83% and a high debt-to-equity ratio of 2.48. The company has reported a decline in net sales at an annual rate of -9.74%, although it did achieve a quarterly net sales high of USD 62.47 million recently.

The stock's price-to-book ratio stands at 28.40, reflecting a premium valuation despite the company's current financial difficulties. Additionally, institutional holdings are notable at 47.41%, suggesting a level of confidence among larger investors, even as the stock faces headwinds in profitability and growth.